The Europe Drug Eluting Stent Market would witness market growth of 8.1% CAGR during the forecast period (2023-2030). In the year 2020, the Europe market's volume surged to 3,989.0 thousand units, showcasing a growth of 7.4% (2019-2022).
Drug-eluting stents (DES) have fundamentally altered and transformed the interventional landscape and made angioplasty more predictable, spurring the market for these devices to expand. By incorporating medication therapy directly into the stent, DES represents a considerable advancement over conventional angioplasty. Numerous advantages of this minimally invasive procedure include decreased stress to blood vessels, quicker recuperation durations, and lower complication risks.
Furthermore, the drug eluting stent market has been focused recently due to increased device development, advancements in adjunctive pharmacology, and improved information systems. Even for the most difficult lesions, restenosis is expected to decline due to quick technological advances in stent design and delivery technologies. The introduction of technologically upgraded stents by major market participants is expected to reduce the incidence of early and late thrombosis.
New avenues for percutaneous coronary interventions in treating cardiovascular diseases have been made possible by developing drug eluting stents. Bioresorbable polymers are being developed and introduced to prevent restenosis, ensure patient safety, and enhance the procedure's therapeutic results. Several market participants have put much effort into R&D and have introduced improved stents made of bioresorbable polymers. The DES ensures minimal tissue injury while enabling quicker vessel repair.
Germany has seen a surge in coronary artery diseases in recent years. More than 800,000 people currently receive invasive diagnostic and therapeutic operations for coronary artery disease (CAD) in Germany each year, according to a Government of Germany article titled The Treatment of Coronary Artery Disease. By the turn of the millennium, 65,000 coronary artery bypass grafting (CABG) procedures were performed annually. These factors will expand the market in the Europe region.
The Germany market dominated the Europe Drug Eluting Stent Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $835 million by 2030. The UK market is exhibiting a CAGR of 7.2% during (2023 - 2030). Additionally, The France market would experience a CAGR of 8.9% during (2023 - 2030).
Based on Application, the market is segmented into Coronary Artery Disease, and Peripheral Artery Disease. Based on Coating Type, the market is segmented into Polymer-based Coating (Non-biodegradable Polymers, and Biodegradable Polymers), and Polymer-free Coating (Micro Porous Surface, Micro Structured Surface, Slotted Tubular Surface, and Nanoporous Surface). Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Drug Eluting Stent Market will Hit $13.2 Billion by 2030, at a CAGR of 8.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Terumo Corporation, Medtronic PLC, Biosensors International Group, Ltd. (Blue Sail Medical Co., Ltd.), Cook Medical, Inc. (Cook Group), B. Braun Melsungen AG, Biotronik SE & Co. KG, Lepu Medical Technology Co., Ltd and Alvimedica.
By Application (Volume, Thousand Units, USD Million, 2019-2030)
By Coating Type (Volume, Thousand Units, USD Million, 2019-2030)
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
